Aviso: Este sitio agrega datos públicos oficiales de la FDA, ClinicalTrials.gov, PubMed y SEC EDGAR solo como referencia general. No constituye asesoramiento médico, diagnóstico, recomendaciones de tratamiento ni asesoramiento de inversión.

Ensayo clínico

Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

NCT: NCT07224880 · COMPLETED

ID NCTNCT07224880
EstadoCOMPLETED
Fecha de inicio2025-10-14
Finalización2026-08-21
SponsorCytrellis Biosystems, Inc. (INDUSTRY)
First posted
Last updated

Resumen breve

The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight loss. The study will also evaluate side effects that occur with this treatment, if any. Standardized 2D Imaging will be used to quantify reduction of wrinkle severity

Fuente oficial

Ver en ClinicalTrials.gov →

Datos obtenidos de la API de ClinicalTrials.gov. Para conocer el estado más reciente, consulte el registro oficial.

↑